The Russian cancer vaccine is ready for use, Izvestia reported, citing Veronika Skvortsova, head of the Federal Medical-Biological Agency.
Preclinical studies have confirmed the safety and efficacy of the drug. At the end of the summer, the FMBA sent documents to the Ministry of Health to obtain permission for clinical use.
As previously reported, from September 2025, the vaccine will be used to treat patients with primary melanoma, as well as those who have undergone certain stages of therapy. The drug was developed by the Gamaleya Research Center for Epidemiology and Microbiology.
Read materials on the topic:
Russian cancer vaccine successfully passed preclinical trials
Cancer vaccine will be free for all Russians